This is a phase III, multicentre, long-term open-label extension of the phase III study: Pearl IIIextension (PGL09-027). During Pearl III (PGL09-026) and subsequent Pearl III extension (PGL09-027), patients have been exposed to a total of 4 cycles of daily 3month open-label treatment with ulipristal acetate 10mg before entering the proposed study Pearl extension 2 (PGL11-024). This proposed study consists of 4 further consecutive courses of 3 months (84 days) open label ulipristal acetate 10mg once daily treatment each separated by a drug free period.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
64
Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
Medical University Vienna
Vienna, Austria
Cliniques Universitaires Saint-Luc, Gynécologie-Obstétrique,
Brussels, Belgium
Myoma symptom control assessed with a Global Study Treatment Satisfaction Questionnaire
Average score of the first 3 questions.
Time frame: 9 months
Myoma symptom control assessed with a Global Study Treatment Satisfaction Questionnaire
Average score of the first 3 questions.
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHR de la Citadelle
Liège, Belgium
Cliniques Universitaires UCL de Mont-Godinne
Yvoir, Belgium
Prywatna Klinika Polozniczo-Ginekologiczna
Bialystok, Poland
INVICTA Sp. Z o.o.
Gdansk, Poland
Private practice
Katowice, Poland
Prywatny Gabinet Lekarski Ginekologia I Poloznictwo Ultrasonografia
Lodz, Poland
Specjalistyczny Gabinet Ginekologiczno-Polozniczy
Lublin, Poland
Gabinet Lekarski Specjalistyczny "Sonus"
Warsaw, Poland
...and 6 more locations